Trials / Completed
CompletedNCT00901186
Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
A Randomized, Open Label, Multicenter, Laser-controlled Phase II Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) vs. Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RFB002 | 0.5 mg |
| PROCEDURE | Laser photocoagulation |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2009-05-13
- Last updated
- 2017-03-03
- Results posted
- 2014-07-03
Locations
17 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00901186. Inclusion in this directory is not an endorsement.